generic

Novartis may have found a buyer for Sandoz; report

Just a few weeks after Novartis revealed it was considering a sale of its generics business Sandoz, there are reports that a potential buyer has already come forward. A report by German newspaper Handelsblatt says that investment group EQT and the German Struengmann family are considering a CHF 20 billion ($21.6 billion) bid for Sandoz …

Novartis may have found a buyer for Sandoz; report Read More »

EU fines Teva and Cephalon €60.5m for ‘pay for delay’ scheme

The European Union has fined Teva and its neurology unit Cephalon €60.5 million for an elaborate “pay for delay” scheme that prevented cheaper generic competition for its sleep disorder drug Provigil (modafinil).  In a statement the EU said the scheme prevented generic competition for Provigil, which is used to treat narcolepsy, after its main patents …

EU fines Teva and Cephalon €60.5m for ‘pay for delay’ scheme Read More »

FTC clears Mylan merger with Pfizer’s Upjohn – with conditions

Mylan’s $12 billion takeover of Pfizer’s Upjohn unit has been cleared by the US authorities, but on the condition that the two companies divest various generic drug products. The Federal Trade Commission (FTC) has ruled that the combined company – to be called Viatris – could have an anticompetitive position in the US market for …

FTC clears Mylan merger with Pfizer’s Upjohn – with conditions Read More »